Overview
Hyloris Pharmaceuticals operates with a management team including Chairman Stefan Yee, who brings over 35 years of experience in corporate finance, M&A, and governance. The company maintains investor relations, governance structures, and a product portfolio organized into categories including Mavericks, Core Drivers, and Promising Seeds.
Key people
In the news
- Yes we can!💚
- Great to be part of this journey: We add value through reinventing existing medications for unmet patient needs worldwide 🫶🌎
- Last week, we came together in Belgium for our annual International Week. 🌍 Four days of sessions, conversations, and honest exchanges. We covered a lot of ground from extensive project reviews and laboratory science updates to sessions on AI tools, and commercial strategy for both Europe and the US. We also made space for lessons learned, failures, and what we'd do differently. That kind of honesty is how teams get better. But the real value wasn't in the agenda. It was in the room. Spending time like this - away from the
- AGM outcomes and new Chair.📰 We welcomed shareholders representing 48.50% of our Hyloris Pharmaceuticals shares at the meeting where all agenda items and proposed resolutions were approved. The Meeting also granted discharge to the members of the Board of Directors and to the statutory auditor for the financial year ending 31 December 2025. 2025 was a year of strong execution for Hyloris marked by tangible progress across development, partnering and commercialization. Looking ahead, we remain focused on disciplined execution and
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.